Fangzhu Lin
YOU?
Author Swipe
View article: Supporting Video 01 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 01 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Time lapse imaging of untreated U2OS cells followed for 16h. Cells divide normally.
View article: Suporting Video Legends from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Suporting Video Legends from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
SV1-SV6: Time lapse imaging of untreated, Arry-520 and ispinesib treated naive U2OS cells, Eg5(D130) and Eg5(L214) expressing U2OS cells followed for 16h. SV7-SV12: Molecular dynamics simulations of either Eg5(WT), or Eg5(D130) or Eg5(L214…
View article: Supporting Video 11 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 11 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Molecular dynamics simulations of the Eg5(D130A)-Arry-520 complex.
View article: Supporting Video 10 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 10 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Molecular dynamics simulations of the Eg5(L214A)-ispinesib complex.
View article: Supporting Video 09 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 09 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Molecular dynamics simulations of the Eg5(L214A)-Arry-520 complex.
View article: Supporting Video 08 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 08 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Molecular dynamics simulations of the wild type Eg5-ispinesib complex.
View article: Supporting Video 08 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 08 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Molecular dynamics simulations of the wild type Eg5-ispinesib complex.
View article: Supplementary Table 1 and Supplementary Figures 1-3 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supplementary Table 1 and Supplementary Figures 1-3 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Table S1: Crystallographic table of data corresponding to the Eg5-Arry-520 complexes. Figure S1: Interactions of the inhibitor and conformational changes upon inhibitor binding. Figure S2: Surface representation of the allosteric inhibitor…
View article: Supporting Video 07 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 07 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Molecular dynamics simulations of the wild type Eg5-Arry-520 complex.
View article: Supporting Video 07 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 07 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Molecular dynamics simulations of the wild type Eg5-Arry-520 complex.
View article: Supporting Video 06 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 06 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Time lapse imaging of U2OS-Eg5(L214A) expressing cells exposed to 10 nM ispinesib and followed for 16h. Cells are arrested in mitosis.
View article: Supporting Video 10 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 10 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Molecular dynamics simulations of the Eg5(L214A)-ispinesib complex.
View article: Supporting Video 06 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 06 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Time lapse imaging of U2OS-Eg5(L214A) expressing cells exposed to 10 nM ispinesib and followed for 16h. Cells are arrested in mitosis.
View article: Supporting Video 11 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 11 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Molecular dynamics simulations of the Eg5(D130A)-Arry-520 complex.
View article: Supporting Video 05 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 05 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Time lapse imaging of U2OS-Eg5(D130A) expressing cells exposed to 10 nM ispinesib and followed for 16h. Cells divide uninhibited.
View article: Data from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Data from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Arry-520 is an advanced drug candidate from the Eg5 inhibitor class undergoing clinical evaluation in patients with relapsed or refractory multiple myeloma. Here, we show by structural analysis that Arry-520 binds stoichiometrically to the…
View article: Supporting Video 03 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 03 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Time lapse imaging of U2OS-Eg5(D130A) expressing cells exposed to 10 nM Arry-520 and followed for 16 h. Cells divide uninhibited.
View article: Supplementary Table 1 and Supplementary Figures 1-3 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supplementary Table 1 and Supplementary Figures 1-3 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Table S1: Crystallographic table of data corresponding to the Eg5-Arry-520 complexes. Figure S1: Interactions of the inhibitor and conformational changes upon inhibitor binding. Figure S2: Surface representation of the allosteric inhibitor…
View article: Supporting Video 02 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 02 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Time lapse imaging of U2OS cells exposed to 10 nM Arry-520 and followed for 16h. Cells are arrested in mitosis.
View article: Supporting Video 04 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 04 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Time lapse imaging of U2OS-Eg5(L214A) expressing cells exposed to 10 nM Arry-520 and followed for 16h. Cells divide uninhibited.
View article: Supporting Video 04 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 04 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Time lapse imaging of U2OS-Eg5(L214A) expressing cells exposed to 10 nM Arry-520 and followed for 16h. Cells divide uninhibited.
View article: Supporting Video 12 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 12 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Molecular dynamics simulations of the Eg5(D130A)-ispinesib complex.
View article: Suporting Video Legends from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Suporting Video Legends from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
SV1-SV6: Time lapse imaging of untreated, Arry-520 and ispinesib treated naive U2OS cells, Eg5(D130) and Eg5(L214) expressing U2OS cells followed for 16h. SV7-SV12: Molecular dynamics simulations of either Eg5(WT), or Eg5(D130) or Eg5(L214…
View article: Supporting Video 12 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 12 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Molecular dynamics simulations of the Eg5(D130A)-ispinesib complex.
View article: Supporting Video 09 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 09 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Molecular dynamics simulations of the Eg5(L214A)-Arry-520 complex.
View article: Data from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Data from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Arry-520 is an advanced drug candidate from the Eg5 inhibitor class undergoing clinical evaluation in patients with relapsed or refractory multiple myeloma. Here, we show by structural analysis that Arry-520 binds stoichiometrically to the…
View article: Supporting Video 02 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 02 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Time lapse imaging of U2OS cells exposed to 10 nM Arry-520 and followed for 16h. Cells are arrested in mitosis.
View article: Supporting Video 01 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 01 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Time lapse imaging of untreated U2OS cells followed for 16h. Cells divide normally.
View article: Supporting Video 03 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 03 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Time lapse imaging of U2OS-Eg5(D130A) expressing cells exposed to 10 nM Arry-520 and followed for 16 h. Cells divide uninhibited.
View article: Supporting Video 05 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Supporting Video 05 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes Open
Time lapse imaging of U2OS-Eg5(D130A) expressing cells exposed to 10 nM ispinesib and followed for 16h. Cells divide uninhibited.